Skip to content
Open access

Treatment Sequencing of CDK4/6 Inhibitors in Bone-Only Hormone Receptor-Positive Metastatic Breast Cancer: Multi-Center Real-World Data Revealing a Numerical Trend Favoring Later-Line Use

Aug 2026 · Cancers · Vol 18 · 0 citations · 27 references
Medicine

TL;DR

Real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis, and first-line use showed a trend toward longer PFS, while later-line use showed a numerical trend toward longer OS.

Abstract

Simple Summary Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are standard first-line treatments for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC). However, the optimal sequencing of CDK4/6i for patients presenting with bone-only disease (BoD) remains unclear. In this multi-center retrospective study of 282 patients with baseline BoD, we compared progression-free survival (PFS) and overall survival (OS) between patients receiving CDK4/6i in first-line versus second- or later-line settings. While first-line use showed a trend toward longer PFS, later-line use showed a numerical trend toward longer OS, which lost statistical significance in multivariate analysis. These real-world findings highlight the need for personalized treatment sequencing in HR+/HER2− MBC patients presenting with bone-only metastasis.

Read PDF

Similar papers

Open access Aug 2026

Impact of HER2-low status on survival outcomes in patients with metastatic breast cancer treated with cdk4/6 inhibitors: A single-center experience

It was unable to demonstrate an association between HER2 status and PFS or OS among patients receiving CDK4/6 inhibitor therapy, and the clinical significance of HER2 status in patients treated with CDK4/6 inhibitors remains unclear.

Esra Aydın, Ç. Öztürk, Oğuzhan Okçu et al. · 0 citations
Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · 0 citations
Open access Sep 2026

First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam

Objective This study aimed to characterize the tumor response rate, progression-free survival (PFS), and overall survival (OS) among patients with HR-positive, HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors plus endocrine therapy at Ho Chi Minh City Oncology Hospital. Secondary objectives included i...

Thị Phan, Hoang Quy Nguyen · 1 citation
Open access Sep 2026

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

Background Real-world data analyses show durable benefits with elacestrant, with or without prior treatment with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). This cohort focused on patients with ER-positive/HER2-negative estrogen receptor 1 (ESR1)-mutated metastatic breast cancer (mBC) treated with elacestrant afte...

G. Curigliano, M. de Laurentiis, N. Harbeck et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.